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 Abstrak 
 
Walaupun, terapi antikoagulan konvensional terbukti berkesan dalam trombosis vena dalam 
dan embolisme pulmonari namun terdapat beberapa kelemahan dalam terapi ini seperti 
lebam, sakit, bengkak atau batuk berdarah. Oleh itu, usaha untuk menghasilkan 
antikoagulan yang novel yang berasal daripada bahan-bahan semula jadi seperti tumbuh-
tumbuhan dituntut pada masa kini. Ocimum sanctum juga dikenali sebagai Ocimum 
tenuiform (OT), Tulsi atau selasih suci yang berasal daripada keluarga Lamiaceae telah 
digunakan secara meluas untuk beribu-ribu tahun dalam perubatan Ayurveda dan sistem 
Unani untuk menyembuhkan atau mencegah beberapa penyakit seperti sakit kepala, demam 
malaria, ulser, bronkitis, batuk, selesema, sakit tekak dan asma. Tujuan kajian ini adalah 
untuk menyiasat kesan ekstrak daun Ocimum sanctum (Tulsi) terhadap prothrombin time 
(PT), activated partial tromboplastin time (APTT) dan thrombin time (TT) dalam plasma 
manusia. Aktiviti pembekuan O.sanctum disiasat melalui ujian PT, APTT dan TT dalam 
plasma citrated yang diperolehi daripada tiga puluh enam penderma darah yang sihat. 
Plasma ini diuji dalam beberapa kepekatan O.sanctum iaitu 0.1mg/ml, 0.5mg/ml dan 
1.0mg/ml. Hasil kajian mendapati ekstrak akueus Ocimum sanctum menunjukkan masa 
yang lebih panjang bagi ujian PT dan APTT  (p <0.05) tetapi tidak memberi kesan kepada 
ujian TT (p> 0.05). Analisis GCMS telah mendapati asid linolenik pada 1-10% etanol dan 
akueus di masa tahanan yang berbeza yang bertanggungjawab bagi aktiviti-aktiviti 
pembekuan Ocimum sanctum dalam plasma manusia. Kesimpulannya, kajian ini 
menunjukkan bahawa Ocimum sanctum menjejaskan aktiviti pembekuan dalam plasma 
manusia dan boleh berpotensi digunakan sebagai produk antikoagulan semulajadi yang 
boleh diperolehi pada masa depan. 
X 
 Abstract 
Even tough, the conventional anticoagulant therapy proven to be effective in deep vein 
thrombosis and pulmonary embolism but there are several drawbacks such as bruises, pain, 
swelling or coughing blood. Therefore, the search for novel anticoagulant derived from 
natural substances like plants are demanded nowadays. Ocimum sanctum also known as 
Ocimum tenuiform (OT), tulsi or holy basil from the family of Lamiaceae has been widely 
used for thousands of years in Ayurveda and Unani system to cure or prevent a number of 
illness such as headache, malaria fever, ulcers, bronchitis, cough, flu, sore throat and 
asthma. The aim of this study is to investigate the effect of Ocimum sanctum (Tulsi) leaf 
extract on prothrombin time (PT), activated partial thromboplastin time (APTT) and 
thrombin time (TT) in human plasma. The coagulation activity of O.sanctum was measure 
via PT, APTT and TT assay in citrated plasma collected from thirty-six healthy regular 
blood donors. The plasma was tested against different concentration of O.sanctum aqueous 
extract as follows 0.1mg/ml, 0.5mg/ml and 1.0mg/ml. The result showed, the aqueous 
extract of O.sanctum prolonged the PT and APTT assays (p<0.05) but no affect on TT 
assay (p>0.05). The GCMS analysis had identified the linolenic acid at 1-10% of ethanol 
and aqueous concentration at different retention time which was responsible for the 
coagulation activities of O.sanctum in human plasma.  In conclusion, this study suggests 
that O.sanctum does affect coagulation activity in human plasma and can be potentially 
used as naturally derived anticoagulant products in future. 
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 CHAPTER 1 
Introduction 
1.1 Blood Coagulation 
Haemostasis is the normal physiological process of blood clotting which involves 
dissolving and lysing of clotted blood. Haemostasis can be divided into two major systems 
as follows; primary and secondary haemostasis (Abdel-Wahab et al., 2006). These two 
processes happen concurrently and interrelated. The primary haemostasis is a short lived 
which involves platelets and vascular response to vessel injury which lead to the formation 
of initial ‘platelet plug’. The vascular wall is lined with endothelial cells which show 
antithrombotic properties due to coagulation inhibitors, neutral phospholipids and 
fibrinolysis activators (Anshu et al., 2014).  
On the other hand, the sub endothelial layer contains collagen and laminin which is highly 
thrombogenic. As a result, vasoconstriction slows the blood flow at the damaged blood 
vessel to limit the blood loss which usually last up to 30 minutes. These process is mediated 
by two controls; local and systemic controls. The local controls are the vasoconstrictors 
such as thromboxane (produced at injured site) whereas systemic control is the epinephrine 
produced by adrenal glands to stimulate vasoconstriction (Cohen, 2014). In addition, 
vasoconstriction enhances the platelet adhesion and activation which in turn lead to platelet 
accumulation and prevent blood loss.  
Meanwhile, the secondary haemostasis is the formation of insoluble fibrin which is 
produced via proteolytic coagulation cascade. These insoluble fibrin meshes were then 
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 incorporated into the platelet plug formed during primary haemostasis which will enhance 
and stabilize the blood clot (Gale, 2011). Secondary haemostasis involves coagulation 
factors and fibrinolytic system in respond to injury. 
Blood coagulation is a complex process that forms blood clots to block/heal a lesion which 
involves cellular (platelet) and protein (coagulation factors). Mostly the coagulation factors 
are precursors of proteolytic enzymes, zymogens which circulate in an inactive form and a 
suffixing letter ‘a’ will be given to the activated zymogen (Anshu et al., 2014). Clotting 
factors are classified into three groups as follows; fibrinogen family, Vitamin K dependent 
proteins and contact family (Table 1.1). In addition, coagulation process is control by 
inhibitor (plasminogen & protein C) which disrupt the clot formation as well as 
development of thrombus.  
 
Table 1.1: Classification of coagulation factors. ( Anshu et al., 2014) 
Blood coagulation system can be divided into three pathways; extrinsic, intrinsic and 
common pathways which are enzymatic cascade that is activated upon tissue damage 
(Rehan et al., 2001). 
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 1.1.1 Extrinsic Pathway 
Based on figure 1.1, extrinsic pathway involves vascular and blood components which are 
activated upon the release of tissue factor/tissue factor pathway (Factor III) at the site of 
injury and takes up to 10-15seconds to complete the entire process (Dorothy et al., 2012). 
Tissue factor is a glycoprotein which is found on surface of subendothelial tissue and 
exposed during vascular injury. Similar to activation of factor IXa in intrinsic pathway, 
tissue factor act as a cofactor for Factor VIIa which contain serine protease that cleaves 
factor X to Factor Xa in the presence of  calcium ions. The association between factor VIIa 
and tissue factor is the principal step in clotting cascade. Next, factor Xa and factor Va 
convert prothrombin/factor II to thrombin which then cleaves fibrinogen to fibrin. 
Furthermore, inhibition of extrinsic pathway by Tissue Factor Pathway Inhibitor (TFPI) 
occurs at factor VIIa-Xa complex (Gale 2011). TFPI also known as lipoprotein-associated 
coagulation inhibitor (LACI) consist of 3 protease inhibitor domains as follows, domain 1 
will bind to factor Xa whereas domain 2 binds will to factor VIIa with the presence of 
factor Xa (Anshu et al., 2014). 
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 1.1.2 Intrinsic Pathway  
Meanwhile, the intrinsic/contact pathway is activated when the blood contact with the 
negatively charged substances such as endothelial surface,prekallikrein, collagen, 
phospholipids or high-molecular-weight kninogen (HMWK)(Figure 1.1). Factor I, II, V, 
VIII, IX and XII plays an important role in these pathway (Anshu et al 2014). Upon 
conversion of prekallikrein to kallikrein, it activates factor XII to XIIa which then activates 
factor XI to XIa. Factor XIa then activates factor IX (vitamin K dependent) to IXa in the 
presence of calcium ions. Factor VIIa and Factor IXa forms complexes with phospholipid 
which then activate factor Xa. Similar to extrinsic pathway, activation of Factor Xa convert 
prothrombin to thrombin which then cleaves fibrinogen to fibrin. Furthermore, the 
production of thrombin can be controlled via negative feedback with the activation of 
Protein C (Gale, 2011). Protein C binds to thrombomodulin and promotes the degradation 
of factor Va and VIIIa which then inhibits the activation of prothrombin.  
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 1.1.3 Common Pathway 
The common pathway is the meeting point of extrinsic and intrinsic pathway in which 
factors I, II, V and X takes part. Factor Xa convert prothrombin to thrombin which then 
cleaves fibrinogen to fibrin. The generation of Factor V, VIII, Thrombin, antithrombin and 
Protein C will either enhance or inhibit thrombin production via positive or negative 
feedback. In positive feedback regulation, factor Va and VIIIa will enhance thrombin 
production by activating prothrombin or factor Xa (Dorothy et al., 2012). Meanwhile, in 
negative feedback, Protein C will bind to thrombomodulin and promotes the degradation of 
factor Va and VIIIa which then inhibits the activation of prothrombin (Gale, 2011). Thus, 
these regulations prevent excessive blood loss which could lead to stroke or heart attack.  
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 1.1.4 Fibrinolytic system 
The final step in haemostasis involves the fibrinolytic system which is parallel to the 
activation of coagulation cascade. Fibrinolytic system involves primarily three serine 
proteases enzymes which dissolves fibrin clot into fibrin degradation products (FDPs) 
(Raber,1990). Plasmin is produced from inactive plasminogen in liver by proteases tissue-
type plasminogen activator (TPA) as well as urokinase-type plasminogen activator (uPA). 
Plasmin activity is inhibited by α-2 antiplasmin and α-2Macroglobulin which prevent 
fibrinolysis (Dorothy et al., 2012). Meanwhile, plasminogen activator inhibitor main 
inhibitor of fibrinolysis which act by inhibiting t-PA and u-PA (Anshu et al.,2014) In 
addition, thrombin activatable fibrinolysis inhibitor (TAFI) which is a proenzyme produced 
by liver and is activated by thrombin act by reducing  the affinity of plasminogen to fibrin 
(Bouma & Mosnier, 2006).   
 
 
Figure 1.1: The overall blood clotting cascade (Crooks and Hart 2015) 
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 1.2 Haemostasis Screening Assay 
Prothrombin time (PT), activated partial thromboplastin time (APTT) and thrombin time 
(TT) are used to detect the blood coagulation disorder.  PT assay measure the deficiencies 
in the extrinsic and common pathway but does not measure Factor XIII activity or intrinsic 
pathway (Behera, et al., 2010). Meanwhile, the APTT measures the intrinsic and common 
pathways but does not measure factors VII and XIII. The TT assay measures the rate of 
conversion of fibrinogen to fibrin. 
1.2.1 PT Assay 
PT measure the time taken to produce fibrin upon the activation of factor VII. In PT assay, 
citrated plasma is used together with an activating agent; thromboplastin prepared from 
rabbit cerebral tissue (Raber,1990). The plasma is incubated at 37 °C and the times taken 
for the fibrin filaments to be formed are measured. The normal reference range for PT assay 
is between 12.2 -14.2 sec.  If there is deficiency in coagulation factor or presence of 
coagulation inhibitor, PT will be prolonged. Thus, the test is repeated with 1:1 mix with 
normal plasma. PT assay is more sensitive in detecting in factor deficiencies than APTT 
(Dorothy et al 2012). PT is important in detecting inherited or acquired deficiencies. 
Inherited deficiency of factor VII will have prolonged PT which is a rare bleeding disorder, 
but PT become normal when mixed with normal plasma (1:1). Meanwhile, acquired 
deficiencies are due to warfarin therapy or liver disease.  
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 1.2.2 APTT Assay  
APTT is also known as Kaolin Cephalin Clotting time (KCCT) or Partial Thromboplastin 
Time with kaolin (PTK). APTT is used to test for inherited or acquired factor deficiencies. 
In inherited disorder such Hemophilia A (FVIII deficiency) and Hemophilia B (FIX 
deficiency), APTT will be prolonged (Gale, 2011). Meanwhile, acquired factor deficiency 
can be due to liver dysfunction and vitamin K deficiency which are more common. APTT 
measure the time taken to produce fibrin upon the activation of intrinsic pathway. A 
prolonged APTT will be seen if any of these factors, prothrombin, fibrinogen, factors V, 
VIII, IX, X, XI and XII are abnormal (Cohen, 2014).  In laboratory, citrated plasma, 
cephalin, an activating agent (kaolin) and calcium ions are added together and followed by 
incubation at 37 °C (Anshu et al.,2014). The time taken for the clumping of kaolin will be 
measured. Kaolin is surface activator which binds to FXII and activates to FXIIa. 
Meanwhile, cephalin is a phospholipid derived from rabbit cerebral tissue, used to replace 
platelet phospholipids which are necessary for the normal function of coagulation cascade.  
The normal range for APTT is 31.7-44 sec. A prolonged APTT can be seen either in the 
presence of inhibitor for intrinsic pathway or reduced activity of the factors (<30%). This 
can be further differentiated via mixing study which uses normal and patient plasma in a 
ratio of 1:1. If the result is completely corrected, then the prolonged APTT is due to factor 
deficiencies. Meanwhile, if the result is still abnormal, then the prolonged APTT is due to 
presence of inhibitor such as antithrombins which disrupt the activity of thrombin in 
conversion of fibrinogen to fibrin (Raber, 1990). However, APTT will shows normal result 
if the factor is approximately 50%. 
   8 
 1.2.3 TT Assay 
TT assay measures the time taken for the conversion of fibrinogen to fibrin in the presence 
of thrombin. Usually TT assay tests for the acquired deficiency of fibrinogen which is due 
to coagulopathy or severe liver disease. In this test, citrated plasma and thrombin are added 
together then incubated at 37 °C (Raber, 1990). The time taken for the formation of fibrin 
filaments is measured. The normal range for TT assay is 15-20sec. Abnormalities of TT 
assay can be due to three reasons. First, it can be due to deficiency in volume of fibrinogen 
(<100 mg/dl) (Choi et al., 2003). In addition, it also can be due to the presence of inhibitor 
(heparin or fibrin degradation products, FDP) or abnormal fibrinogen. Similar to APTT and 
PT, mixing study can be performed in 1:1 ratio to distinguish between deficiency of 
fibrinogen or decrease in fibrinogen.  
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 1.3 Blood Coagulation Disorders 
Blood coagulation factors and platelet are the two crucial components to maintain 
haemostatis. Bleeding disorder can be inherited or acquired and occur due to deficiency to 
any of the components. Examples of inherited bleeding disorder are von Willebrand’s 
disease and haemophilia A whereas example of acquired bleeding disorder is liver disease. 
These disease can be treated with antifibrinolytic or procoagulant to enhance coagulation 
cascade. In addition, the formation of blots/thrombus (thrombosis) can also lead to various 
diseases such as pulmonary embolism and cerebral vascular accident (CVA) (Pandey and 
Madhuri, 2010). However, anticoagulant therapy can be given to prevent thrombus 
formation. Anticoagulant can be obtained by two ways; conventional therapy (drug) or 
natural/herbal medicine. 
There are number of drugs used as anticoagulant; vitamin K antagonist (VKA), non-VKA 
(Apixaban), (Caumadin) and heparin (Enoxaparin and Porcine) .Vitamin K antagonist are 
drugs that reduce fibrin production by manipulating vitamin K activity. Warfarin is an 
example of oral VKA that inhibits the enzyme, Vitamin K epoxide reductase which 
involves in oxidation of vitamin K (Mphil et al., 2014). Since factor II, VII, IX and X 
requires vitamin K to be activated, thus by reducing the production of vitamin K will 
prevent the formation for thrombin (Grover et al., 2005).Non -VKA also known as novel 
oral anticoagulant (NOAC) such as apixaban and edoxaban are new alternative drugs which 
directly binds to thrombin. These drugs have wide therapeutic window (Bauer, 2013). 
 On the other hand, Heparin can be divided into two types as follows; unfractionated 
heparin (UFH) and low molecular weight heparin (LMWH) (Hirsh & Rashke, 2004). UFH 
10 
 is a mixture of sulphated glycosaminoglycans with a molecular weight of 3,000-30,000 
daltons. UFH (Porcine) is an intravenous anticoagulant that activates antithrombin III 
followed by the inactivation of thrombin and factor Xa involves in blood clotting cascade 
(Anand et al., 2001).  Meanwhile, LMWH is obtained from unfractionated heparin via 
enzymatic and chemical depolymerization with a molecular weight 4,500-5,000 dalton. 
Similar to UFH, LMWH also activates antithrombin III which is mediated by 
pentasaccharide sequence but with a lower affinity.  
Even tough, the conventional therapy proven to be effective in deep vein thrombosis and 
pulmonary embolism but there are several drawbacks such as bruises, pain, swelling or 
coughing blood. The main adverse effect associated with warfarin is bleeding which is 
about 7.2 and 1.3 per 100 patient-years according to meta- analysis by Choi et al., (2003). 
However, for a newer anticoagulant such as apixaban and edoxaban , these drugs have a 
wider therapeutic window which make the laboratory monitoring difficult.  In addition, 
these drugs have uncertainty of drugs dosing in some patient populations such as patient 
with underlying chronic disease (Bauer, 2013).  
Therefore, the study of natural substances with anticoagulation properties that present in 
vegetables and plants has been widely explored to replace the currently available 
anticoagulant drugs. One of the natural substances that have anticoagulant properties is 
linolenic acid which is present in Ocimum sanctum. Hence this study is performed to look 
at the basic coagulation screening which is PT, APTT and TT at various aqueous 
concentration of Ocimum sanctum in vitro. 
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 1.4 Objectives 
1.4.1 General Objectives 
 To study the effects of Ocimum sanctum leaves extracts on human blood 
coagulation activities in vitro. 
1.4.2 Specific Objectives 
 To determine the effects of different aqueous extract concentration of Ocimum 
sanctum leaves on prothrombhin time (PT) activated partial thromboplastin time 
(APTT) and thrombin time (TT) assays. 
 To identify the linolenic acid present in Ocimum sanctum leaves in aqueous and 
ethanol extract that involves in blood coagulation activities via Gas 
Chromatographic Mass Spectrometry (GCMS). 
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 1.5  Hypothesis 
     HA: Ocimum sanctum leaves enhance the blood coagulation activities of human in in 
vitro. 
     H0: Ocimum sanctum leaves have no affects on blood coagulation activities. 
1.6 Expected outcome 
There are blood coagulation activities in aqueous extract of Ocimum sanctum which can be 
determined using PT, APTT, TT assays in vitro. This outcome benefits in clinical treatment 
as it possess procoagulant or anticoagulant. If the Ocimum sanctum acts as anticoagulant 
(prevent blood clotting) then, it can be used for treatment of thrombosis such as pulmonary 
embolism and deep vein thrombosis. Meanwhile, if Ocimum sanctum acts as procoagulant 
(promotes blood coagulation) then it can be used to treat acute bleeding and hemorrhage 
The other expected of this study is to look at compositions of Ocimum sanctum that 
enhance blood coagulation activities which can be identified in ethanol and aqueous extract 
using GCMS. If this is presence, this OS can be potentially used as alternative 
anticoagulant/procoagulant agents.  
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 CHAPTER 2 
LITERATURE REVIEW 
2.1 Ocimum sanctum  
Ocimum sanctum (OS) (figure 2.1) also known as Ocimum tenuiform (OT), tulsi or holy 
basil from the family of Lamiaceae has been widely used for thousands of years in 
Ayurveda and Unani system to cure or prevent a number of illness such as headache, 
malaria fever, ulcers, bronchitis, cough, flu, sore throat and asthma (Jung et al., 2002). 
Tulsi, the ‘Queen of herbs’ can be divided into three types; Rama/light tulsi (OS), 
Shyama/Dark tulsi (OS) and Vana tulsi (OT) which have similar chemical properties and 
medicinal values.  
 
Figure 2.1: Ocimum sanctum 
14 
 2.1.1 Structure 
OS is an erect plant, 30-60cm tall with green/purple leaves that are fragrant and hairy 
stems. The aromatic leaves are oblong, ovate, petiole, sharp point or blunt and toothed or 
non toothed which grow up to 5cm long (Kadian and Parle, 2012). Stems and branches are 
purplish in color, sometimes woody below.  Meanwhile, the flowers are elongate racemes 
and small in size. The seeds are flat and reddish-yellow in color. The fruits are small in 
size.  
2.1.2 Classification 
Scientific classification: 
Rank Scientific Name and Common name 
Kingdom Plantae-Plants 
Subkingdom Tracheobionta-Vascular plants 
Superdivision Spermatophyta-seed plants 
Division Magnoliophyta-Flowering plants 
Class Magnoliopsida-Dicotyledons 
Subclass Asteridae 
Order Lamiales 
Family Lamiaceae –Mint family 
Genus Ocimum L.-basil 
Species Ocimum sanctum L- holy basil 
Adapted from Natural Resources Conservation Service, United States Department of 
Agriculture 
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 2.1.3 Geographical Distribution 
OS is widespread as cultivated plant for medicinal/ religious purposes and distributed all 
over the world tropics (Madhuri and Pandey , 2010). OS is grown in India from Andaman 
and Nicobar islands up to 1800m above the sea level of Himalayas (Ali et al.,2006). In 
addition, it also found in Australia, West Africa, Malaysia and some part of Arab countries.  
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 2.1.4 Active Compounds 
2.1.4.1 Phytoconstituents 
Based on table 2.1, the phytochemicals presents in OS can be obtained from various part of 
the plant via fixed oil, essential oil, mineral contents and alcoholic extract. The leaves 
extract of OS consist of 0.7% of volatile oil which includes 71% of eugenol (major 
component) and 20% methyl eugenol (Kadian and Parle, 2012). In addition, the oil also 
contains sesquiterpine hydrocarbon caryophyllene and carvacrol. Meanwhile, stem and 
leaves extract of OS will yield phenolic compounds such as apigenin, circimaritin and 
rosameric acid (Gautam and Goel, 2014). On the other hand, linoleic acid, linolenic acid 
and stearic acid can be obtained from seeds via fixed oil extracts.  In addition, vitamin A, 
calcium, copper and iron are derived from the entire plant via extract of mineral contents. 
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 Table 2.1: Phytochemical constituents of Ocimum sanctum (Kadian and Parle, 2012) 
No/s Extract Phytochemicals Plants Parts 
1 Fixed oil Linoleic acid, Linolenic acid, Oleic acid, Palmitric 
acid, Stearic acid. 
Seeds 
2 Essential oil Aromadendrene oxide, Benzaldehyde, Borneol, 
Bornyl acetate,Camphor, Caryophyllene oxide, cis-
Terpineol, Cubenol,Cardinene, D-Limonene, 
Eicosane Eucalyptol, Eugenol,Farnesene, Farnesol, 
Furaldehyde, Germacrene, Heptanol,Humulene, 
Limonene, n-butylbenzoate, Ocimene, Oleic acid, 
Sabinene, Selinene, Phytol, Veridifloro, _-
Camphene, _-Myrcene, _Pinene, _-Pinene, _-
Thujene, _-Guaiene, _-Gurjunene, methyl chavicol 
and linalool. 
Leaves 
3 Mineral 
contents 
Vitamin C, Vitamin A, Calcium, Phosphours, 
Chromium, Copper,Zink, Iron. 
Whole Plant 
4 Alcoholic 
extract 
Aesculectin, Aesculin, Apgenin, Caffiec acid, 
Chlorgenic Acid,Circineol, Gallic Acid, Galuteolin, 
Isorientin, Isovitexin, Luteolin, Molludistin, 
Orientin, Procatechuic acid, Stigmsterol,Urosolic 
acid, Vallinin, Viceni, Vitexin, Vllinin acid. 
Leaves/areal 
parts 
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 2.1.5 Medicinal Values 
2.1.5.1 Pharmacological activities 
There are number of pre clinical studies in animals’ models and in vitro testing that have 
been carried out to report the pharmacological activities of OS. It has been reported that OS 
leaves extract in petroleum, ethanol and aqueous have wound healing activity, anticancer, 
antidiabetic, antioxidant, anti-inflammatory and anticoagulation properties.   
2.1.5.2 Wound Healing Activity 
In a study done by Shetty et al., (2006), the effect of aqueous extract of OS in wound 
healing on rats has been investigated. In this study, the albino rats were divided into two 
groups irrespective to sex, group 1: wounded control rats whereas group 2: wounded rats 
given OS aquoeus extract. The wound healing had been monitored via wound 
breaking/contraction strength in incision/excision wound model and epithelization period. 
The result showed an increase in percent of wound contraction in rats given with OS 
extract. Thus, OS can be used to manage any abnormal healing such hypertropic scars.  
Similarly, another study done by Shetty et al in 2006, the ethanolic extract of OS leaves 
were used to investigate normal wound healing versus dexamethasone depressed wound 
model. The result showed that, the extract increases the wound breaking/contraction 
strength and wound epithelializes rapidly as compared o dexamethasone. Thus, it can be 
said that OS ethanolic extract promotes wound healing as well as overcome the suppression 
action of dexamethasone (Shetty et al., 2006).  
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 2.1.5.3 Anticancer 
In 1999, Govindasamy and his colleagues have done an investigation regarding 
chemopreventive effect of OS versus 7,12-dimethylbenz (a) anthracene (DMBA) on 
hamster buccal pouch carcinogenesis. In this study, OS was given in three forms; aqueous 
extract, fresh leaf paste and ethanolic extract. OS was given orally and topically applied to 
the buccal pouch of hamster which was exposed to 0.5% DMBA. As a result, the 
production of squamous cell carcinoma and papillomas were reduced and thus increase the 
survival rate. In addition, the aqueous extract showed higher chemopreventive effect than 
the other two forms which was proven via histopathological observations.  
Similarly, Gupta and Prakash (2000) investigated the chemopreventive activity of OS seed 
oil versus 20-methylcholanthrene induced tumors in the thigh of albino mice. As a result, 
the chemopreventive effect and antioxidant properties of OS seed oil disrupt tumor 
production and thus enhance survival rate of albino mice.  
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 2.1.5.4 Antidiabetic 
The oral administration of OS ethanolic extract has been reported to reduce blood sugar 
level in normal, urea and glucose fed hyperglycemic with marked increases in insulin and 
glycogen tolerance in streptozotocin-induced diabetic rats (Kandasamy et al., 2006). In 
addition, the use OS ethanolic extract has also increase the production of C-peptide. In 
another study done by Abdel-Wahab et al., (2006) which used four types of OS extract 
butanol, aqueous, ethylacetate and ethanol which were studied on the insulin production as 
well as mechanism of action of every extract. As a result, it shows that ethanol extract 
stimulate the production of insulin from isolated islets, perfused pancreas and clonal 
pancreatic beta cells but the other extraction decrease the production.  In 2006, Ali et al., 
reported that OS induce the production of insulin which reflects its antidiabetic property. 
However, the oral administration of OS does not have any effect on hyperinsulinemia 
(Grover et al.,2005). 
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 2.1.5.5 Antioxidant: 
Another property of OS is antioxidant which is due to the presence of flavonoids. In 2000, a 
study conducted by DeWitt et al., stated that orientin and vicenin (flavonoids) in vitro were 
expressed in radiation induced lipid peroxidation in mouse liver. Therefore, the OS extract 
able to react with highly reactive free radicals. Meanwhile, the aqueous extract of OS has 
the ability to increase the antioxidant activity of superoxide dismutase which is an enzyme 
catalyze the reaction of superoxide to oxygen or hydrogen peroxide (Gupta et al., 2006). 
On the other hand, Acharya et al., (2004), has investigated the effect of methanolic extract 
of OS on hypoperfusion and cerebral reperfusion on rats. Thus, OS extract decreased the 
superoxide dismutase (SOD) activity as well as lipid peroxidation. In conclusion, OS can 
be used to treat cerebrovascular insufficiency as well as reperfusion injury.  
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